184 related articles for article (PubMed ID: 37838759)
41. JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia.
Bodaar K; Yamagata N; Barthe A; Landrigan J; Chonghaile TN; Burns M; Stevenson KE; Devidas M; Loh ML; Hunger SP; Wood B; Silverman LB; Teachey DT; Meijerink JP; Letai A; Gutierrez A
Leukemia; 2022 Jun; 36(6):1499-1507. PubMed ID: 35411095
[TBL] [Abstract][Full Text] [Related]
42. BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells.
Moujalled D; Southon AG; Saleh E; Brinkmann K; Ke F; Iliopoulos M; Cross RS; Jenkins MR; Nhu D; Wang Z; Shi MX; Kluck RM; Lessene G; Grabow S; Bush AI; Strasser A
Cell Death Differ; 2022 Jul; 29(7):1335-1348. PubMed ID: 35332309
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of BH3 mimetics as a combination therapy with irradiation in head and neck squamous cell carcinoma.
Korelin K; Oostveen M; Wahbi W; Ianevski F; Cavalcante B; Turunen L; Belevich I; Al-Samadi A; Salo T
Biomed Pharmacother; 2024 Jun; 175():116719. PubMed ID: 38749173
[TBL] [Abstract][Full Text] [Related]
44. Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics.
Korell F; Olson ML; Salas-Benito D; Leick MB; Larson RC; Bouffard A; Silva H; Gasparetto A; Berger TR; Kann MC; Mergen M; Kienka T; Wehrli M; Haradhvala NJ; Bailey SR; Letai A; Maus MV
Sci Transl Med; 2024 Jun; 16(750):eadk7640. PubMed ID: 38838132
[TBL] [Abstract][Full Text] [Related]
45. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
[TBL] [Abstract][Full Text] [Related]
46. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
[TBL] [Abstract][Full Text] [Related]
47. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388).
Khurana A; Shafer DA
Onco Targets Ther; 2019; 12():2903-2910. PubMed ID: 31289443
[TBL] [Abstract][Full Text] [Related]
48. HTLV-1-associated adult T cell leukemia is highly susceptible to Navitoclax due to enhanced Bax expression.
Witzens-Harig M; Giaisi M; Köhler R; Krammer PH; Li-Weber M
Int J Cancer; 2016 Jan; 138(2):507-14. PubMed ID: 26260669
[TBL] [Abstract][Full Text] [Related]
49. Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.
Arai S; Jonas O; Whitman MA; Corey E; Balk SP; Chen S
Clin Cancer Res; 2018 Nov; 24(21):5458-5470. PubMed ID: 30021909
[No Abstract] [Full Text] [Related]
50. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Pullarkat VA; Lacayo NJ; Jabbour E; Rubnitz JE; Bajel A; Laetsch TW; Leonard J; Colace SI; Khaw SL; Fleming SA; Mattison RJ; Norris R; Opferman JT; Roberts KG; Zhao Y; Qu C; Badawi M; Schmidt M; Tong B; Pesko JC; Sun Y; Ross JA; Vishwamitra D; Rosenwinkel L; Kim SY; Jacobson A; Mullighan CG; Alexander TB; Stock W
Cancer Discov; 2021 Jun; 11(6):1440-1453. PubMed ID: 33593877
[TBL] [Abstract][Full Text] [Related]
51. Combination of ABT-737 and resveratrol enhances DNA damage and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells.
Opydo-Chanek M; Rak A; Cierniak A; Mazur L
Toxicol In Vitro; 2017 Aug; 42():38-46. PubMed ID: 28366708
[TBL] [Abstract][Full Text] [Related]
52. DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis.
Milani M; Byrne DP; Greaves G; Butterworth M; Cohen GM; Eyers PA; Varadarajan S
Cell Death Dis; 2017 Jan; 8(1):e2552. PubMed ID: 28079887
[TBL] [Abstract][Full Text] [Related]
53. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer.
Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
Cells; 2024 Mar; 13(6):. PubMed ID: 38534371
[TBL] [Abstract][Full Text] [Related]
54. Synergistic Effect of Venetoclax and Bendamustine in Early T-cell Precursor Acute Lymphoblastic Leukemia.
Nguyen HDT; LE TM; Lee D; Cho HJ; Lee J; Sohn SK; Kim JG; Ham JY; Moon JH; Han HS; Kim J; Baek DW
In Vivo; 2024; 38(4):1740-1749. PubMed ID: 38936885
[TBL] [Abstract][Full Text] [Related]
55. Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells.
Yang M; Wang L; Ni M; Neuber B; Wang S; Gong W; Sauer T; Sellner L; Schubert ML; Hückelhoven-Krauss A; Hong J; Zhu L; Kleist C; Eckstein V; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
Front Immunol; 2020; 11():608167. PubMed ID: 33362794
[TBL] [Abstract][Full Text] [Related]
56. Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition.
Aptullahoglu E; Ciardullo C; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768733
[TBL] [Abstract][Full Text] [Related]
57. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
Turner BC; Eves T; Refaeli Y
DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
[TBL] [Abstract][Full Text] [Related]
58. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.
Kang MH; Kang YH; Szymanska B; Wilczynska-Kalak U; Sheard MA; Harned TM; Lock RB; Reynolds CP
Blood; 2007 Sep; 110(6):2057-66. PubMed ID: 17536015
[TBL] [Abstract][Full Text] [Related]
59. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
Govaerts I; Prieto C; Vandersmissen C; Gielen O; Jacobs K; Provost S; Nittner D; Maertens J; Boeckx N; De Keersmaecker K; Segers H; Cools J
J Hematol Oncol; 2021 Jun; 14(1):97. PubMed ID: 34167562
[TBL] [Abstract][Full Text] [Related]
60. Stayin' alive: BCL-2 proteins in the hematopoietic system.
Zehnle PMA; Wu Y; Pommerening H; Erlacher M
Exp Hematol; 2022 Jun; 110():1-12. PubMed ID: 35315320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]